Table 2 Characteristics of the follow-up population diagnosed with gastric cancer and studied for PD-L1 overexpression.
From: PD-L1 expression in gastric cancer assessed with antibodies 28-8 and 22C3
Follow-up patients | |||||
|---|---|---|---|---|---|
Characteristic | Male | Female | Total | p-value | |
n | 20 (58.8%) | 14 (41.2%) | 34 (100%) | ||
Age (SD) | 62.1 (10.9) | 55 (14.4) | 59 (12.7) | ||
Differentiation | Poorly | 7 (35%) | 5 (35.7%) | 12 (35.3%) | 0.9 |
Moderate | 4 (20%) | 3 (21.4%) | 7 (20.6%) | ||
Non-specific | 9 (45%) | 6 (42.9%) | 15(44.1%) | ||
Lauren classification | Tubular-intestinal patron | 1 (5%) | 0 (0%) | 1 (3%) | |
Rings cells | 2 (10%) | 4 (28.6%) | 6 (17.6%) | ||
PD-L1 clone 22c3 | 20 (100%) | 14 (100%) | 34 (100%) | ||
Positive | 6 (30%) | 6 (42.9%) | 12 (35.3) | ||
Negative | 14 (70%) | 8 (57.1%) | 22 (64.7%) | ||
CPS 1–4 | 0 (0%) | 4 (66.7%) | 4 (33.3%) | ||
CPS 5–9 | 3 (50%) | 0 (0%) | 3 (25%) | ||
CPS > 10 | 3 (50%) | 2 (33.3%) | 5 (41.7%) | ||
Metastasis | Yes | 1 (5%) | 5(35.7%) | 6(17.6%) | (OR: 0.09 (0.009–0.9.009.9 IC 95% p = 0.02) |
No | 19 (95%) | 9 (64.3%) | 28 (82.4%) | ||
Area | Cardioesophageal Junction | 0 (0%) | 1 (20%) | 1 (16.6%) | |
Peritoneum | 0 (0%) | 2 (40%) | 2 (33.3%) | ||
Cervical Lymph Node | 1 (100%) | 0 (0%) | 1 (16.6%) | ||
Round Ligament | 0 (0%) | 1 (20%) | 1 (16.6%) | ||
Gastrocolic Ligament | 0 (0%) | 1 (20%) | 1 (16.6%) | ||
Immunotherapy | Yes | 8 (40%) | 4 (28.6%) | 12 (35.3%) | |
No | 12 (60%) | 10 (71.4%) | 22 (64.7%) | ||
PD-L1 positive | 2 (33.3%) | 2 (33.3%) | 4 (33.3%) | ||
PD-L1 negative | 6 (42.9%) | 2 (25%) | 8 (66.7%) | ||
